GlobeNewswire Inc.T3·4mo ago
RNAC Cartesian Therapeutics, Inc. Common Stock
XNAS
6.42
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
RNAC
$6.42
—
Key stats
$6.42
- 52-Week Range
- $5.60 – $11.00
- YTD
- -5.03%
- IV Rank (30D)
- 23.1
- Straddle Price
- $2.05
- P/C Vol Ratio
- 0.75
- Market Cap
- $0.2B
- Open
- $6.42
- Day Range
- $6.40 – $6.71
- Volume
- 105,973
- Prev Close
- $6.39
Fair Value
-50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.09% |
| Beta vs SPY | 2.09 |
| Cost of Equity (CAPM) | 16.58% (VRP-adj) |
| WACC | 14.02% |
| Volatility Risk Premium | +181.8pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | 122.9% |
| Book / Price | -72.1% |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | -5322.4% |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $8.18 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $6.94 |
| Bollinger Width / SMA20 | 386.1% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $0B |
Peers used for multiples: ABUS, BTSG, CDNA, CON, HAE, HRMY, KRYS, OPCH
Blended Fair Value
$0.18
Deviation
-50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 27.8× · 8 peers |
| Peer EV/EBITDA | n/a | 0% | median 15.9× · 8 peers |
| Peer P/B | n/a | 0% | median 6.2× · 8 peers |
| Peer P/S | $0.18 | 100% | median 3.1× · 8 peers |
| Market Anchor (SMA50) | $8.18 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $5.97 | 0% | 7 strikes · skew +0.60 |
As of 2026-10-21 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.2B
- Employees
- 75
- List Date
- 2016-06-22
- CIK
- 0001453687
- Next Earnings
- 2026-11-05 (After-Close)
- EPS Forecast
- ($1.02) (3 est.)
- Headquarters
- Frederick, MD
- Homepage
- https://www.cartesiantherapeutics.com
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|
| Jan | -- | 9.89% | 14.06% | 1.04% | 8.33% |
| Feb | -- | -2.47% | -5.28% | 11.78% | 1.34% |
| Mar | -- | -5.80% | -24.69% | -19.08% | -16.52% |
| Apr | -- | 31.35% | -3.92% | -2.66% | 8.26% |
| May | -- | 53.36% | -22.09% | 21.22% | 17.50% |
| Jun | -- | -24.97% | 4.11% | 50.58% | 9.91% |
| Jul | -- | -32.84% | 17.63% | -25.22% | -13.48% |
| Aug | -- | -9.76% | -18.49% | 17.92% | -3.44% |
| Sep | -- | 22.87% | 3.86% | -22.47% | 1.42% |
| Oct | -- | 15.72% | -20.21% | -11.08%* | -5.19% |
| Nov | 26.17% | -4.32% | -7.87% | -- | 4.66% |
| Dec | -30.36% | -8.48% | -1.23% | -- | -13.36% |
| Total | -12.14% | 15.14% | -54.15% | -1.28% | -13.11% |
* Only 4 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $6.87
SMA 50: $8.14
SMA 200: $7.69
Current: $6.42
EMA 12: $6.61
EMA 26: $7.10
MACD: -0.4881 | Signal: 0.0018
BEARISH
ADX (14): 17.99
RANGE
+DI: 17.20
−DI: 26.90
Momentum Oscillators
RSI (14): 35.89
NEUTRAL
Stoch %K: 14.13
Stoch %D: 9.43
Williams %R: -79.90
Volume & Volatility
BB Upper: $7.72
BB Lower: $6.02
NEUTRAL
OBV: 3,717,626
Vol SMA 20: 158,122
Vol ROC: 22.60%
ATR: $0.43
True Range: $0.31
HV 20: 50.3%
HV 30: 43.9%
HV 60: 50.4%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall Assessment: BULLISH (Confidence Level: 8/10)
Key Drivers:
- Strong recent news headlines highlighting pipeline expansion, financing, and positive market outlook
- Bullish technical signals from MACD and RSI indicators
- High volatility indicating potential for significant price movements
Primary Risks:
- High beta value indicating high risk relative to the broader market
- Unusual options activity suggesting a potentially inflated move
2-3 Sentence Investment Thesis: RNAC presents a compelling long-term investment opportunity, driven by its pipeline expansion and positive news sentiment. However, investors should exercise caution due to the stock's high volatility and potential for significant price movements.
Recent News Sentiment Impact: The recent news headlines have been overwhelmingly positive, highlighting pipeline expansions and financing deals. This has contributed to the bullish technical signals and increasing confidence in the investment thesis.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Bullish
- Medium-term (1-3 months): Neutral
- Long-term (3-12 months): Bullish
Support/Resistance Levels:
- Upper Bollinger Band: $10.64
- Middle Bollinger Band: $9.46
- Lower Bollinger Band: $8.29
Momentum Signals: RSI interpretation: 41.75 (neutral) MACD signal: Bullish Bollinger Bands position: Neutral
Volume Analysis:
- Volume SMA 20: 116500.75
- On-Balance Volume (OBV): 5510550.19
- Volume Rate of Change: -3.49%
News & Sentiment Analysis
Recent Headlines Summary: The recent news headlines have been overwhelmingly positive, highlighting pipeline expansions and financing deals.
Sentiment Assessment: Aggregate sentiment is POSITIVE, with all recent headlines contributing to this assessment.
Catalyst Identification: Upcoming events include the AURORA trial top-line data release in Q1 2027, which could further drive price movements.
Market Narrative: The news sentiment has been aligning with technical signals, reinforcing the bullish trend and increasing confidence in the investment thesis.
Risk & Volatility Assessment
Beta Interpretation: High-risk stock relative to the broader market (beta >1.66)
Volatility Regime: Current volatility is higher than historical levels, indicating potential for significant price movements.
Options Market Signals: IV rank: 8.8% (Low) Put/call ratios: 0.00 (Bullish sentiment) Unusual activity: High volume of calls and low put volume
Downside Protection: Support levels include the lower Bollinger Band ($8.29) and the SMA 50 ($9.02).
Market Context & Positioning
Sector Performance: RNAC is outperforming its sector peers.
Institutional Activity: Volume patterns suggest institutional interest in the stock.
Correlation Analysis: The stock moves more than the market (R-squared = 0.25), indicating high volatility.
Relative Valuation: The stock is trading within a relatively tight range, with no clear signs of overvaluation or undervaluation.
Key Levels & Action Items
Critical Price Levels:
- Upper Bollinger Band: $10.64
- Middle Bollinger Band: $9.46
- Lower Bollinger Band: $8.29
Breakout/Breakdown Levels:
- SMA 50: $9.02 (resistance)
- EMA 12: $9.25 (support)
Time-Sensitive Catalysts:
- AURORA trial top-line data release in Q1 2027
Risk Management: Stop-loss levels should be set around the lower Bollinger Band ($8.29) to protect against potential downside risks.
Conclusion RNAC presents a compelling long-term investment opportunity, driven by its pipeline expansion and positive news sentiment. However, investors should exercise caution due to the stock's high volatility and potential for significant price movements. A comprehensive analysis framework has been used to provide an objective assessment of the stock, highlighting key drivers, primary risks, and market context.
Generated
News
All RNAC news →
GlobeNewswire Inc.T3·4mo ago
GlobeNewswire Inc.T3·5mo ago
GlobeNewswire Inc.T3·5mo ago
GlobeNewswire Inc.T3·6mo ago
GlobeNewswire Inc.T3·9mo ago
BenzingaT3·9mo ago
BenzingaT3·15mo ago
GlobeNewswire Inc.T3·17mo ago
BenzingaT3·18mo ago
Showing 1–10 of 37
Page 1 of 4
Earnings History
8 of 8 under expected move
Avg Expected Move
100.56%
Avg Actual Move
4.47%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-05-08 | After-Close | 250.59% | 5.98% | 0.02x | Within |
| 2024-08-08 | After-Close | 300.00% | 3.89% | 0.01x | Within |
| 2025-05-08 | After-Close | 39.83% | 4.99% | 0.13x | Within |
| 2025-08-07 | Pre-Market | 39.89% | 6.56% | 0.16x | Within |
| 2025-11-06 | After-Close | 61.59% | 4.24% | 0.07x | Within |
| 2026-03-09 | After-Close | 36.31% | 5.21% | 0.14x | Within |
| 2026-04-30 | Pre-Market | 42.89% | 3.86% | 0.09x | Within |
| 2026-08-06 | After-Close | 33.39% | 1.03% | 0.03x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
RNAC Options Activity & IV Rank
RNAC IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 137.5%
7-DTE IV: —
Expected Move: $2.05
7-DTE Move: $2.05
Days to Exp: 30 (2026-11-20)
Options Flow
Call Volume: 355
Put Volume: 268
P/C Volume: 0.755
NEUTRAL
Call OI: 535
Put OI: 285
P/C OI: 0.533
Total OI: 820
ATM Options Pricing
ATM Call: $0.53
ATM Put: $1.52
Call %: 8.2%
Put %: 23.8%
Chain Summary
Chain Volume: 1,822
Chain OI: 2,639
Last Updated: 10/21/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 35th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
35%
vs own history
GEX tilt
+0.12
OI-weighted, today
Vanna tilt
+0.20
δ-sensitivity to IV
Charm tilt
-0.12
δ-decay vs time
? What is this?
· 4 ATM contracts, 1k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 21 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 21 · ATM 112.5% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)23.1LowOct 21
Straddle Price (30 DTE)$2.05Oct 21
Beta Analysis
Risk Metrics
Beta: 1.4485
Alpha: -25.74%
Correlation: 0.2223
R-Squared: 4.9%
Stock Volatility: 82.8%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
RNAC Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 27,173,064 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
3 filers$1.56M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $1.35M | 86.47% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $141.71K | 9.07% | 2026-06-30 |
| 3 | Simplex Trading, LLC Custodian | $69.81K | 4.47% | 2026-06-30 |
3 filers$355.32K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $212.57K | 59.82% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $112.54K | 31.67% | 2026-06-30 |
| 3 | Simplex Trading, LLC Custodian | $30.22K | 8.50% | 2026-06-30 |
RNAC Insider Trading (Form 4)
Latest: 2026-04-06Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-04-06 | Murat Kalayoglu | 10%+ Owner | Exer (M) | +758,001 | — | EDGAR | |
| 2026-04-06 | Seven One Eight Three Four Irrevocable Trust | 10%+ Owner | Exer (M) | +1,516,002 | — | EDGAR | |
| 2026-03-13 | Michael Singer | Director | Gift (G) | −6,555 | — | EDGAR | |
| 2026-01-08 | Milos Miljkovic | Chief Medical Officer | Sell (S) | −3,573 | $6.82 | -$24.4K | EDGAR |
| 2026-01-08 | Carsten Brunn | President and CEO | Sell (S) | −23,766 | $6.82 | -$162.1K | EDGAR |
| 2026-01-08 | Blaine Davis | Chief Financial Officer | Sell (S) | −10,591 | $6.82 | -$72.2K | EDGAR |
| 2026-01-06 | June Ann Seymour | Chief Accounting Officer | Award (A) | +6,500 | — | EDGAR | |
| 2026-01-06 | Emily English | Chief Operations Officer | Award (A) | +24,000 | — | EDGAR | |
| 2026-01-06 | Blaine Davis | Chief Financial Officer | Award (A) | +37,000 | — | EDGAR | |
| 2026-01-06 | Kemal Malik | Director | Award (A) | +2,600 | — | EDGAR | |
| 2026-01-06 | Timothy C Barabe | Director | Award (A) | +2,600 | — | EDGAR | |
| 2026-01-06 | Carsten Brunn | President and CEO | Award (A) | +143,200 | — | EDGAR | |
| 2026-01-06 | Nishan M DeSilva | Director | Award (A) | +2,600 | — | EDGAR | |
| 2026-01-06 | Milos Miljkovic | Chief Medical Officer | Award (A) | +27,000 | — | EDGAR | |
| 2026-01-06 | Patrick J Zenner | Director | Award (A) | +2,600 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
RNAC Insider Holdings
17 insiders · @ $6.42
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Timothy A Springer | Director | 9,302,798 | $59.72M | $16.68M | 18 | 2026-01-06 |
| 2 | Murat Kalayoglu | Director | 5,820,260 | $37.37M | $0 | 7 | 2026-04-06 |
| 3 | Seven One Eight Three Four Irrevocable Trust | 10%+ Owner | 506,999 | $3.25M | $0 | 3 | 2026-04-06 |
| 4 | Carsten Brunn | President and CEO | 323,530 | $2.08M | -$451.8K | 6 | 2026-01-08 |
| 5 | Michael Singer | Director | 145,797 | $936.0K | $0 | 9 | 2026-03-13 |
| 6 | Blaine Davis | Chief Financial Officer | 121,220 | $778.2K | -$206.3K | 6 | 2026-01-08 |
| 7 | Emily English | Chief Operations Officer | 94,226 | $604.9K | -$30.1K | 8 | 2026-01-06 |
| 8 | Christopher M Jewell | Chief Scientific Officer | 62,490 | $401.2K | -$917.8K | 8 | 2025-01-13 |
| 9 | Metin Kurtoglu | Chief Technology Officer | 62,258 | $399.7K | -$2.51M | 8 | 2025-01-07 |
| 10 | Milos Miljkovic | Chief Medical Officer | 58,820 | $377.6K | -$963.4K | 8 | 2026-01-08 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
RNAC Board & Officers
As of SEC filings through Apr 6, 2026Directors 8
- Timothy A Springer · since Jun 21, 2016
- Timothy C Barabe · since Jul 29, 2016
- Patrick J Zenner · since Jun 16, 2017
- Carsten Brunn · since Dec 1, 2018
- Nishan M DeSilva · since Jun 23, 2021
- Michael Singer · since Nov 13, 2023
- Kemal Malik · since Jul 1, 2024
- Adrian Ion Bot · since Dec 16, 2025
Officers 5
- Carsten Brunn · President and CEO · since Dec 1, 2018
- Blaine Davis · Chief Financial Officer · since Nov 28, 2022
- Milos Miljkovic · Chief Medical Officer · since Nov 13, 2023
- Emily English · Chief Operations Officer · listed since Jan 2025
- June Ann Seymour · Chief Accounting Officer · since Oct 27, 2025
10% owners 4
- Elizabeth Hoge · since Nov 13, 2023
- Murat Kalayoglu · since Nov 13, 2023
- Seven One Eight Three Four Irrevocable Trust (entity) · since Nov 13, 2023
- Timothy A Springer · listed since Jun 2019
Changes in the last 10 years (50)
| Mar 26, 2026 | The company announced the departure of Murat Kalayoglu from the board in an SEC filing |
| Dec 16, 2025 | Adrian Ion Bot became a director |
| Oct 29, 2025 | The company announced the departure of Carrie Smith Cox from the board in an SEC filing |
| Oct 27, 2025 | June Ann Seymour became Chief Accounting Officer |
| Apr 29, 2025 | The company announced the departure of Metin Kurtoglu as Chief Technology Officer in an SEC filing |
| Jan 6, 2025 | Emily English listed as Chief Operations Officer (previously SVP, Head of Manufacturing) in SEC filings |
| Jul 1, 2024 | Kemal Malik became a director |
| Apr 10, 2024 | Michael Singer no longer listed as a 10% owner in SEC filings |
| Apr 10, 2024 | Metin Kurtoglu listed as Chief Technology Officer (previously Chief Operations Officer) in SEC filings |
| Apr 9, 2024 | Emily English became SVP, Head of Manufacturing |
| Feb 28, 2024 | The company announced the departure of Aymeric Sallin from the board in an SEC filing |
| Nov 21, 2023 | The company announced the departure of Scott Dunseth Myers from the board in an SEC filing |
| Nov 13, 2023 | The company announced the departure of Takashi Kei Kishimoto as Chief Scientific Officer in an SEC filing |
| Nov 13, 2023 | The company announced the departure of Peter G Traber as Chief Medical Officer in an SEC filing |
| Nov 13, 2023 | The company announced the departure of Lloyd P. Johnston as Chief Operations Officer in an SEC filing |
| Nov 13, 2023 | Seven One Eight Three Four Irrevocable Trust became a 10% owner |
| Nov 13, 2023 | Murat Kalayoglu became a director |
| Nov 13, 2023 | Murat Kalayoglu became a 10% owner |
| Nov 13, 2023 | Milos Miljkovic became Chief Medical Officer |
| Nov 13, 2023 | Michael Singer became a director |
| Nov 13, 2023 | Michael Singer became a 10% owner |
| Nov 13, 2023 | Metin Kurtoglu became Chief Operations Officer |
| Nov 13, 2023 | Elizabeth Hoge became a 10% owner |
| Nov 13, 2023 | Christopher M Jewell became Chief Scientific Officer |
| Jan 4, 2023 | The company announced the departure of Goran Ando from the board in an SEC filing |
| Nov 28, 2022 | Blaine Davis became Chief Financial Officer |
| Nov 22, 2022 | The company announced the departure of Kevin Tan as Chief Financial Officer in an SEC filing |
| Oct 5, 2021 | Lloyd P. Johnston listed as Chief Operations Officer (previously COO and SVP, R&D) in SEC filings |
| Sep 20, 2021 | Kevin Tan became Chief Financial Officer |
| Jun 23, 2021 | Nishan M DeSilva became a director |
| Aug 1, 2020 | Peter G Traber became Chief Medical Officer |
| Apr 24, 2020 | Goran Ando became a director |
| Nov 20, 2019 | Carrie Smith Cox became a director |
| Sep 3, 2019 | Bradford D. Dahms became Chief Financial Officer |
| Jul 15, 2019 | Alison D. Schecter became Chief Medical Officer |
| Jun 18, 2019 | Timothy A Springer first listed as a 10% owner in an SEC filing |
| Jun 14, 2019 | Scott Dunseth Myers became a director |
| May 7, 2019 | Ann K. Donohue became Controller |
| Mar 20, 2019 | Elona Esq. Kogan became General Counsel |
| Dec 1, 2018 | Carsten Brunn became a director |
| Dec 1, 2018 | Carsten Brunn became President and CEO |
| Nov 14, 2017 | David Abraham listed as GC, CCO & Corporate Secretary (previously CCO, GC and Corp. Sec.) in SEC filings |
| Oct 26, 2017 | Stephen Smolinski became Chief Commercial Officer |
| Oct 26, 2017 | John Harold Leaman became CFO, Treas. & Hd Corp Strategy |
| Jul 11, 2017 | Werner Cautreels no longer listed as a 10% owner in SEC filings |
| Jul 11, 2017 | David Siewers listed as CFO and Treasurer (previously Chief Financial Officer) in SEC filings |
| Jul 6, 2017 | Lloyd P. Johnston no longer listed as a 10% owner in SEC filings |
| Jun 20, 2017 | Amir Nashat no longer listed as a 10% owner in SEC filings |
| Jun 19, 2017 | Lloyd P. Johnston first listed as a 10% owner in an SEC filing |
| Jun 16, 2017 | Patrick J Zenner became a director |
Not reported recently (16)
- Christopher M Jewell · Last reported as Chief Scientific Officer in an SEC filing dated Jan 13, 2025
- Ann K. Donohue · Last reported as Controller in an SEC filing dated Jun 3, 2021
- Bradford D. Dahms · Last reported as Chief Financial Officer in an SEC filing dated Jan 6, 2021
- Stephen Smolinski · Last reported as Chief Commercial Officer in an SEC filing dated Jan 6, 2020
- Elona Esq. Kogan · Last reported as General Counsel in an SEC filing dated Jan 6, 2020
- Alison D. Schecter · Last reported as Chief Medical Officer in an SEC filing dated Jan 6, 2020
- Omid Farokhzad · Last reported as a director in an SEC filing dated Aug 16, 2019
- Amir Nashat · Last reported as a director in an SEC filing dated Jun 18, 2019
- Peter Barton Hutt · Last reported as a director in an SEC filing dated Jun 19, 2018
- David Abraham · Last reported as GC, CCO & Corporate Secretary in an SEC filing dated Jun 19, 2018
- John Harold Leaman · Last reported as CFO, Treas. & Hd Corp Strategy in an SEC filing dated Jun 19, 2018
- Earl Sands · Last reported as Chief Medical Officer in an SEC filing dated Nov 21, 2017
- Werner Cautreels · Last reported as a director in an SEC filing dated Nov 14, 2017
- David Siewers · Last reported as CFO and Treasurer in an SEC filing dated Sep 22, 2017
- Peter Keller · Last reported as Chief Business Officer in an SEC filing dated Jul 11, 2017
- Edwin M Kania Jr · Last reported as a director in an SEC filing dated May 16, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
RNAC Proposed Insider Sales (Form 144)
Latest: 2026-06-09
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-06-09 | MILOS MILJKOVIC | Former Affiliate | 35,038 | $232.7K | 2026-06-09 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-06-02 | MILOS MILJKOVIC | Former Affiliate | 3,924 | $25.2K | 2026-06-02 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-01-13 | CHRISTOPHER M JEWELL | Former Affiliate | 9,000 | $68.9K | 2026-01-13 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-01-09 | CHRISTOPHER M JEWELL | Former Affiliate | 1,510 | $12.1K | 2026-01-09 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2025-11-19 | CHRISTOPHER M JEWELL | Former Affiliate | 26,935 | $192.6K | 2025-11-19 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2024-12-10 | METIN KURTOGLU | Officer | 2,901 | $70.6K | 2024-12-10 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2024-12-09 | METIN KURTOGLU | Officer | 10,763 | $274.5K | 2024-12-09 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2024-11-21 | METIN KURTOGLU | Officer | 32,789 | $546.6K | 2024-11-21 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2024-11-20 | METIN KURTOGLU | Officer | 5,700 | $98.6K | 2024-11-20 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2024-11-19 | METIN KURTOGLU | Officer | 200 | $3.9K | 2024-11-19 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
21 ETFs hold RNAC
21 shown · $9.30M total exposure · 0.00% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $2.7M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.00% | $2.1M | $75.1B | 2026-10-20 |
| 3 | JSML Janus Henderson Small Cap Growth Alpha ETF | Janus | 0.40% | $1.5M | $363.1M | 2026-10-20 |
| 4 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $1.2M | — | 2026-09-30 |
| 5 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.00% | $601,635 | $13.7B | 2026-10-20 |
| 6 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.00% | $547,628 | — | 2026-09-30 |
| 7 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.02% | $258,064 | $1.2B | 2026-10-20 |
| 8 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.00% | $108,210 | $13.6B | 2026-10-20 |
| 9 | QQQS Invesco NASDAQ Future Gen 200 ETF | Invesco | 0.39% | $79,541 | — | 2026-10-20 |
| 10 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.01% | $78,279 | — | 2026-09-30 |
| 11 | RSSL Global X Russell 2000 ETF | Global X | 0.00% | $41,216 | — | 2026-10-21 |
| 12 | EES WisdomTree U.S. SmallCap Fund | Nport | 0.00% | $33,027 | — | 2026-06-30 |
| 13 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.00% | $10,476 | — | 2026-09-30 |
| 14 | ITWO ProShares Russell 2000 High Income ETF | ProShares | 0.00% | $4,860 | — | 2026-10-21 |
| 15 | VTHR Vanguard Russell 3000 ETF | Vanguard | 0.00% | $4,441 | — | 2026-09-30 |
| 16 | URTY ProShares UltraPro Russell2000 | ProShares | 0.00% | $3,788 | — | 2026-10-21 |
| 17 | FSEG Fidelity Enhanced Small Cap Growth ETF | Fidelity | 0.05% | $3,504 | $7.7M | 2026-10-20 |
| 18 | UWM ProShares Ultra Russell2000 | ProShares | 0.00% | $2,452 | — | 2026-10-21 |
| 19 | IBBQ Invesco Nasdaq Biotechnology ETF | Nport | 0.00% | $359 | — | 2026-05-31 |
| 20 | HDG ProShares Hedge Replication ETF | ProShares | 0.00% | $103 | — | 2026-10-21 |
| 21 | RB ProShares Russell 2000 Dynamic Buffer ETF | ProShares | 0.00% | $45 | — | 2026-10-21 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-5.95
TTM Revenue
$1.48M
TTM Net Income
$-153.94M
TTM Op. Cash Flow
$-76.53M
Quarterly figures (11 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | — | $13.72M | $0.46 | $-21.08M |
| Q1 '26 | 2026-03-31 | $78.00K | $-39.18M | $-1.46 | $-22.14M |
| Q4 '25 | 2025-12-31 | $947.00K | $-92.58M | $-3.57 | $-17.71M |
| Q3 '25 | 2025-09-30 | $452.00K | $-35.90M | $-1.38 | $-15.60M |
| Q2 '25 | 2025-06-30 | $298.00K | $13.26M | $0.50 | $-17.52M |
| Q1 '25 | 2025-03-31 | $1.10M | $-17.71M | $-0.68 | $-23.11M |
| Q4 '24 | 2024-12-31 | $-759.00K | $-10.25M | $0.12 | $-7.00M |
| Q3 '24 | 2024-09-30 | $387.00K | $-24.18M | $-1.13 | $13.69M |
| Q2 '24 | 2024-06-30 | $33.45M | $9.63M | $0.54 | $-14.45M |
| Q1 '24 | 2024-03-31 | $5.84M | $-56.82M | $-10.50 | $-15.92M |
| Q4 '23 | 2023-12-31 | $8.27M | $-215.21M | $-41.56 | $-23.29M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-06
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
—
P/S
118.11
EV/EBITDA
—
EV/Sales
53.96
ROE
—
ROA
-48.3%
Div Yield
0.00%
FCF Yield
-43.87%
Debt/Equity
—
Current Ratio
—
Market Cap
$174.45M
as of 2026-10-21
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
1.86M
SI % of Float
15.39%
Days to Cover
12.64
Short Vol Ratio
57.5%
Free Float
12.06M
Float %
41.0%
Short interest 2026-09-30 • Short volume 2026-10-21 • Float 2026-05-13